Eli Lilly and Company (NYSE:LLY) Shares Sold by Krane Funds Advisors LLC

Krane Funds Advisors LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 7.4% in the 3rd quarter, HoldingsChannel reports. The fund owned 388 shares of the company’s stock after selling 31 shares during the quarter. Eli Lilly and Company comprises about 0.3% of Krane Funds Advisors LLC’s investment portfolio, making the stock its 22nd biggest holding. Krane Funds Advisors LLC’s holdings in Eli Lilly and Company were worth $344,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. Lynx Investment Advisory acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at about $32,000. LGT Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $36,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $40,000. Morton Brown Family Wealth LLC grew its holdings in shares of Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after acquiring an additional 15 shares during the period. Finally, Cedar Mountain Advisors LLC raised its holdings in Eli Lilly and Company by 53.3% during the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after purchasing an additional 16 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.1 %

Shares of LLY opened at $917.18 on Friday. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The firm has a market capitalization of $871.69 billion, a P/E ratio of 135.08, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The stock’s fifty day simple moving average is $920.70 and its 200 day simple moving average is $856.27.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, equities research analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Analysts Set New Price Targets

LLY has been the subject of several research reports. Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a research note on Thursday. They set an “outperform” rating and a $1,100.00 price target for the company. Morgan Stanley restated an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Barclays upped their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, Bank of America lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $986.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.